Cargando…

Best treatment options for occult breast cancer: A meta-analysis

OBJECTIVES: Occult breast cancer (OBC) is a rare malignant breast tumor. Because of the rare cases and limited clinical experience, a huge therapeutic difference has existed all over the world and standardized treatments have yet been established. METHODS: A meta-analysis was conducted using MEDLINE...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rong, Yang, Hong-xin, Chen, Jie, Huang, Jian-jun, Lv, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213692/
https://www.ncbi.nlm.nih.gov/pubmed/37251927
http://dx.doi.org/10.3389/fonc.2023.1051232
_version_ 1785047679837929472
author Wang, Rong
Yang, Hong-xin
Chen, Jie
Huang, Jian-jun
Lv, Qing
author_facet Wang, Rong
Yang, Hong-xin
Chen, Jie
Huang, Jian-jun
Lv, Qing
author_sort Wang, Rong
collection PubMed
description OBJECTIVES: Occult breast cancer (OBC) is a rare malignant breast tumor. Because of the rare cases and limited clinical experience, a huge therapeutic difference has existed all over the world and standardized treatments have yet been established. METHODS: A meta-analysis was conducted using MEDLINE and Embase databases to identify the choice of OBC surgical procedures in all studies: (1) patients undergoing axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB) only; (2) patients undergoing ALND with radiotherapy (RT); (3) patients undergoing ALND with breast surgery (BS); (4) patients undergoing ALND with RT and BS; and (5) patients undergoing observation or RT only. The primary endpoints were mortality rates, the second endpoints were distant metastasis and locoregional recurrence. RESULTS: Among the 3,476 patients, 493 (14.2%) undergo ALND or SLNB only; 632 (18.2%) undergo ALND with RT; 1483 (42.7%) undergo ALND with BS; 467 (13.4%) undergo ALND RT and BS, and 401 (11.5%) undergo observation or RT only. After comparing the multiple groups, both groups 1 and 3 have higher mortality rates than group 4 (30.7% vs. 18.6%, p < 0.0001; 25.1% vs. 18.6%, p = 0.007), and group 1 has higher mortality rates than groups 2 and 3 (30.7% vs.14.7%, p < 0.00001; 30.7 vs. 19.4%, p < 0.0001). Group (1 + 3) had a prognosis advantage over group 5 (21.4% vs. 31.0%, p < 0.00001). There was no significant difference both in the distant recurrence rates and locoregional rates between group (1 + 3) and group (2 + 4) (21.0% vs. 9.7%, p = 0.06; 12.3% vs. 6.5%, p = 0.26). CONCLUSION: On the basis of this meta-analysis, our study indicates that BS including modified radical mastectomy (MRM) and breast-conserving surgery (BCS) combined RT may appear as the optimal surgical approach in patients with OBC. RT cannot prolong both the time of distant metastasis and the local recurrences.
format Online
Article
Text
id pubmed-10213692
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102136922023-05-27 Best treatment options for occult breast cancer: A meta-analysis Wang, Rong Yang, Hong-xin Chen, Jie Huang, Jian-jun Lv, Qing Front Oncol Oncology OBJECTIVES: Occult breast cancer (OBC) is a rare malignant breast tumor. Because of the rare cases and limited clinical experience, a huge therapeutic difference has existed all over the world and standardized treatments have yet been established. METHODS: A meta-analysis was conducted using MEDLINE and Embase databases to identify the choice of OBC surgical procedures in all studies: (1) patients undergoing axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB) only; (2) patients undergoing ALND with radiotherapy (RT); (3) patients undergoing ALND with breast surgery (BS); (4) patients undergoing ALND with RT and BS; and (5) patients undergoing observation or RT only. The primary endpoints were mortality rates, the second endpoints were distant metastasis and locoregional recurrence. RESULTS: Among the 3,476 patients, 493 (14.2%) undergo ALND or SLNB only; 632 (18.2%) undergo ALND with RT; 1483 (42.7%) undergo ALND with BS; 467 (13.4%) undergo ALND RT and BS, and 401 (11.5%) undergo observation or RT only. After comparing the multiple groups, both groups 1 and 3 have higher mortality rates than group 4 (30.7% vs. 18.6%, p < 0.0001; 25.1% vs. 18.6%, p = 0.007), and group 1 has higher mortality rates than groups 2 and 3 (30.7% vs.14.7%, p < 0.00001; 30.7 vs. 19.4%, p < 0.0001). Group (1 + 3) had a prognosis advantage over group 5 (21.4% vs. 31.0%, p < 0.00001). There was no significant difference both in the distant recurrence rates and locoregional rates between group (1 + 3) and group (2 + 4) (21.0% vs. 9.7%, p = 0.06; 12.3% vs. 6.5%, p = 0.26). CONCLUSION: On the basis of this meta-analysis, our study indicates that BS including modified radical mastectomy (MRM) and breast-conserving surgery (BCS) combined RT may appear as the optimal surgical approach in patients with OBC. RT cannot prolong both the time of distant metastasis and the local recurrences. Frontiers Media S.A. 2023-05-12 /pmc/articles/PMC10213692/ /pubmed/37251927 http://dx.doi.org/10.3389/fonc.2023.1051232 Text en Copyright © 2023 Wang, Yang, Chen, Huang and Lv https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Rong
Yang, Hong-xin
Chen, Jie
Huang, Jian-jun
Lv, Qing
Best treatment options for occult breast cancer: A meta-analysis
title Best treatment options for occult breast cancer: A meta-analysis
title_full Best treatment options for occult breast cancer: A meta-analysis
title_fullStr Best treatment options for occult breast cancer: A meta-analysis
title_full_unstemmed Best treatment options for occult breast cancer: A meta-analysis
title_short Best treatment options for occult breast cancer: A meta-analysis
title_sort best treatment options for occult breast cancer: a meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213692/
https://www.ncbi.nlm.nih.gov/pubmed/37251927
http://dx.doi.org/10.3389/fonc.2023.1051232
work_keys_str_mv AT wangrong besttreatmentoptionsforoccultbreastcancerametaanalysis
AT yanghongxin besttreatmentoptionsforoccultbreastcancerametaanalysis
AT chenjie besttreatmentoptionsforoccultbreastcancerametaanalysis
AT huangjianjun besttreatmentoptionsforoccultbreastcancerametaanalysis
AT lvqing besttreatmentoptionsforoccultbreastcancerametaanalysis